COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

https://elevartherapeutics.com/

---

CAREER WEBSITE

https://elevartherapeutics.com/elevar-careers/

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Aug 3, 2023

Elevar Therapeutics to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib in Combination with Camrelizumab in Unresectable Hepatocellular Carcinoma (uHCC)

Jul 24, 2023

Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet

Jul 24, 2023

Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet

Jul 17, 2023

Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma

Jun 1, 2023

Elevar Therapeutics to Participate in ASCO 2023 and BIO 2023; New Jersey-based Company Secures State License as It Builds Toward Commercialization

For More Press Releases

---